Suggestions
Michael Koratich
TD2 - Accelerating cancer therapeutic development from "Bench-to-Bedside"!
Michael Koratich is a seasoned professional with over 25 years of experience in cancer therapeutic development.3 He currently serves as the Senior Director of Business Development at Translational Drug Development (TD2), a position he has held since October 2023.2 In this role, he is primarily responsible for preclinical, regulatory consulting, and flow cytometry services.3
Koratich's expertise spans the full spectrum of cancer therapeutic development, from discovery to clinical trials. His technical background includes:
- Leading preclinical IND-enabling studies
- Bioanalytical method development and validation
- Central lab operations
- Strong focus on immuno-oncology3
Throughout his career, Koratich has played a pivotal role in developing advanced flow cytometry techniques, in vitro and in vivo models, and driving innovation in oncology therapeutic development.3 Prior to joining TD2, he held positions at Eurofins Biopharma Services, including Head of Global Business Development for Bioanalytic Services and VP of Integrated Laboratory Services for Eurofins Central Laboratory.3
Koratich is active on LinkedIn, where he frequently shares insights about cancer therapeutic development, preclinical strategies, and advancements in oncology.145 He is based in Arvada, Colorado, United States.6
Highlights
These days, I spend most of my time focused on the Preclinical side of cancer therapeutic development. But, I am always thinking about that future patient and so is Translational Drug Development (TD2).
Here's a blast from the past blog post that covers some of the challenges of early-phase Oncology Clinical Trials. Being ready to address these challenges doesn't start when your IND is approved or even when you're preparing that IND. The best place to start thinking about and preparing for the realities of your future Phase 1 cancer therapeutic clinical trial is as close to the beginning of discovery/development as possible.
TD2 is thinking about your future patient from the beginning of our involvement with your program to help you climb the mountain of cancer therapeutic development from #BenchToBedside.
https://lnkd.in/eZ6YcMTJ
#cancertherapeuticdevelopment #clinicaltrial #cancertherapeutic #preclinical #flowcytometry #bioanalytical #
World Breast Cancer Research Day was yesterday, 18AUG. So this news comes a day late, but close enough. Well done to all the #breastcancerresearchers involved in this work!!!
#worldbreastcancerresearchday #breastcancer #hrpositiveher2negative
